On Fibrinolysis: A. In Pregnancy, Labour, Puerperium and During Treatment with Sex Hormones B. In Human Ontogenesis and in Human Organ Culture

References

• Aaro L. A., Juergens J. L. Thrombophlebitis associated with pregnancy. Amer J. Obstet Gynec 1971; 109: 1128
   PubMed Web of Science ®Google Scholar
• Abildgaard U., Uszynski M. Separation and characterization of two fibrinolytic inhibitors from human placenta. Thrombos Diathes Haemorrh 1971; 25: 580
   Google Scholar
• Ablondi F. B., Hagan J. J., Philips M., De Renzo E. C. Inhibition of plasmin, trypsin and the streptokinase-actived fibrinolytic system by ϵ-aminocaproic acid. Arch Biochem Biophys 1959; 82: 153
   PubMed Web of Science ®Google Scholar
• Albrechtsen O. K. The fibrinolytic activity of human tissues. Brit J Haemat 1957a; 3: 284
   PubMed Web of Science ®Google Scholar
• Albrechtsen O. K. Fibrinolytic activity of animal tissues. Acta Physiol Scand 1957b; 39: 284
   Google Scholar
• Albrechtsen O. K. The fibrinolytic agents in saline extracts of human tissues. Scand J Clin Lab Invest 1958; 10: 91
   PubMed Web of Science ®Google Scholar
• Albrechtsen O. K. Fibrinolytic activity in the organism. Acta Physiol Scand 1959; 47, Suppl. 165
   Google Scholar
• Alkjaersig N., Fletcher A. P., Sherry S. The activation of human plasminogen. I. Spontaneous activation in glycerol. J Biol Chem 1958; 233: 81
   Google Scholar
• Alkjaersig N., Fletcher A. P., Sherry S. The activation of human plasminogen. II. A kinetic study of activation with trypsin, urokinase and streptokinase. J Biol Chem 1958; 233: 86
   PubMedGoogle Scholar
• Alkjaersig N., Fletcher A. P., Sherry S. ϵ-aminocaproic acid: an inhibitor of plasminogen activation. J Biol Chem 1959; 234: 832
   PubMed Web of Science ®Google Scholar
• Andersson L., Nilsson I. M., Liedberg G., Nilsson L., Rybo G., Eriksson O., Granstrand B., Melander B. Antifibrinolytica. Vergleichende Untersuchungen von trans-4-(Aminomethyl)-cyclo-hexancarbonsäure, Aminocapronsäure und p-Aminomethylbenzoesäure. Arzneim Forsch (Drug Res) 1971; 21: 424
   Google Scholar
• Andersson L., Nilsson I. M., Niléhn J.-E., Hedner U., Granstrand B., Melander B. Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scand J. Haemat 1965; 2: 230
   PubMedGoogle Scholar
• Andersson L., Nilsson I. M., Olow B. Fibrinolytic activity in man during surgery. Thrombos Diathes Haemorrh 1962; 7: 391
   PubMedGoogle Scholar
• Aoki N., von Kaulla K. N. The extraction of vascular plasminogen activator from human cadavers and a description of some of its properties. Amer J Clin Path 1971a; 55: 171
   Google Scholar
• Aoki N., von Kaulla K. N. Dissimilarity of human vascular plasminogen activator and human urokinase. J Lab Clin Med 1971b; 78: 354
   PubMed Web of Science ®Google Scholar
• Aoki N., von Kaulla K. N. Human serum plasminogen antiactivator: its distinction from antiplasmin. Amer J. Physiol 1971c; 220: 1137
   Google Scholar
• Astrup T. A proteolytic inhibitor in lung tissue. 18th International Physiology Congress, Copenhagen, 1950; 81, Abstracts
   Google Scholar
• Astrup T. Fibrinokinase. Acta Physiol Scand 1951; 24: 267
   PubMedGoogle Scholar
• Astrup T. Fibrinolysis. Acta Haemat 1952a; 7: 271
   Google Scholar
• Astrup T. Ox lung tissue as a proteolytic inhibitor. Acta Physiol Scand 1952b; 26: 243
   PubMedGoogle Scholar
• Astrup T. Fibrinolysis in the organism. Blood 1956; 11: 781
   PubMed Web of Science ®Google Scholar
• Astrup T. The haemostatic balance. Thrombos Diathes Haemorrh 1958; 2: 347
   Google Scholar
• Astrup T. Tissue activators of plasminogen. Fed Proc 1966; 25: 42
   PubMedGoogle Scholar
• Astrup T. Blood coagulation and fibrinolysis in tissue culture and tissue repair. Biochem Pharmacol Suppl. Pergamon, London 1968; 241
   Google Scholar
• Astrup T., Albrechtsen O. K. Estimation of the plasminogen activator and the trypsin inhibitor in animal and human tissues. Scand J Clin Lab Invest 1957; 9: 233
   PubMed Web of Science ®Google Scholar
• Astrup T., Albrechtsen O. K., Claassen M., Rasmussen J. Thromboplastic and fibrinolytic activity of the human aorta. Circ Res 1959; 7: 969
   Google Scholar
• Astrup T., Glas P., Kok P. Lung fibrinolytic activity and bovine high mountain disease. Proc Soc Exp Biol Med 1968; 127: 373
   Google Scholar
• Astrup T., Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem 1952; 40: 346
   PubMed Web of Science ®Google Scholar
• Astrup T., Permin P. M. Fibrinolysis in the animal organism. Nature 1947; 159: 681
   PubMed Web of Science ®Google Scholar
• Astrup T., Permin P. M. Fibrinokinase and fibrinolytic enzymes. Nature 1948; 161: 689
   Google Scholar
• Astrup T., Rasmussen J., Amery A., Poulsen H. E. Fibrinolytic activity of cirrhotic liver. Nature 1960; 185: 619
   PubMed Web of Science ®Google Scholar
• Astrup T., Stage A. Isolation of a soluble fibrinolytic activator from animal tissue. Nature 1952; 170: 929
   PubMed Web of Science ®Google Scholar
• Astrup T., Sterndorff I. The plasminogen activator in animal tissue. Acta Physiol Scand 1956; 36: 250
   PubMedGoogle Scholar
• Auerswald W., Doleschel W. Critical evaluation of the fibrin plate method for estimating fibrinolytic enzymes and activation. Thrombos Diathes Haemorrh 1960; 5: 112
   Google Scholar
• Bachmann F., Fletcher A. P., Alkjaersig N., Sherry S. Partial purification and properties of the plasminogen activator from pig heart. Biochemistry 1964; 3: 1578
   PubMed Web of Science ®Google Scholar
• Bailar J. C. Thromboembolism and oestrogen therapy. Lancet 1967; 2: 560
   Google Scholar
• Ball A. P., Silver D., Day E. D. Plasminogenfibrinogen complex formation as a prelude to fibrinogenolysis. Thrombos Diathes Haemorrh 1971; 25: 114
   Google Scholar
• Bang N. U., Fletcher A. P., Alkjaersig N., Sherry S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. III. Demonstration of abnormal clot structure by electron microscopy. J Clin Invest 1962; 41: 935
   PubMed Web of Science ®Google Scholar
• Barlow G. H., Summaria L., Robbins K. C. Molecular weight studies on human plasminogen at the microgram level. J Biol Chem 1969; 244: 1138
   Google Scholar
• Barnett E. V., Baron S. An activator of plasminogen produced by cell culture. Proc Soc Exp Biol Med 1959; 102: 308
   Google Scholar
• Barnhart M., Riddle J. M. Cellular localization of profibrinolysin (plasminogen). Blood 1963; 21: 306
   PubMedGoogle Scholar
• Beller F. K., Goessner W., Herrschlein J. Tissue activator of the fibrinolytic system in placental tissue. Obstet Gynec 1962; 20: 117
   Google Scholar
• Berg W., Korsan-Bengtsen K. Separation of human fibrinogen and plasminogen by means of gel filtration. Thrombos Diathes Haemorrh 1963; 9: 151
   PubMedGoogle Scholar
• Bernik M. B., Kwaan H. C. Origin of fibrinolytic activity in cultures of the human kidney. J Lab Clin Med 1967; 70: 650
   PubMed Web of Science ®Google Scholar
• Bernik M. B., Kwaan H. C. Plasminogen activator activity in cultures from human tissues. An immunological and histochemical study. J Clin Invest 1969; 48: 1740
   PubMed Web of Science ®Google Scholar
• Bernik M. B., Kwaan H. C. Inhibitors of fibrinolysis in human tissues in culture. Amer J Physiol 1971; 221: 916
   Google Scholar
• Biezenski J. J., Moore H. C. Fibrinolysis in normal pregnancy. J Clin Path 1958; 11: 306
   PubMed Web of Science ®Google Scholar
• Biggs R., Macfarlane R. G., Pilling J. Observations. on fibrinolysis. Experimental activity produced by exercise or adrenaline. Lancet 1947; 1: 402
   PubMedGoogle Scholar
• Björkman S. E. A new method for enumeration of platelets. Acta Haemat 1959; 22: 377
   PubMedGoogle Scholar
• Björlin G., Pandolfi M., Åstedt B. Release of fibrinolytic activators from human tumours cultured in vitro. Experientia 1972, In press
   Google Scholar
• Blatt W. F., Zylber J., Gray J. L., Jensen A. Mechanism of bovine and human plasminogen activation by human plasmin and streptokinase. Fed Proc 1960; 19: 60
   Google Scholar
• Blix S. Studies on the fibrinolytic system in the euglobulin fraction of human plasma. A. A methodological study. B. Application of the methods. Scand J Clin Lab Invest 1961; 13, Suppl 58
   Google Scholar
• Bonnar J., McNicol G. P., Douglas A. S. Fibrinolytic enzyme system and pregnancy. Brit Med J 1969; 3: 387
   PubMed Web of Science ®Google Scholar
• Bonnar J., McNicol G. P., Douglas A. S. Coagulation and fibrinolytic mechanisms during and after childbirth. Brit Med J 1970; 2: 200
   PubMed Web of Science ®Google Scholar
• Bouma B. N., Hedner U., Nilsson I. M. Typing of fibrinogen degradation products in urine in various clinical disorders. Scand J Clin Lab Invest 1971; 27: 331
   PubMed Web of Science ®Google Scholar
• Brakman P. Bovine fibrinogen without detectable plasminogen. Anal Biochem 1965; 11: 149
   PubMedGoogle Scholar
• Brakman P. The fibrinolytic system in human blood during pregnancy. Amer J Obstet Gynec 1966; 94: 14
   PubMed Web of Science ®Google Scholar
• Brakman P. Fibrinolysis. A standardized fibrin plate metod and a fibrinolytic assay of plasminogen. Scheltema & Holkema, Amsterdam 1967
   Google Scholar
• Brakman P., Astrup T. Selective inhibition in human pregnancy blood of urokinase induced fibrinolysis. Scand J Clin Lab Invest 1963; 15: 603
   PubMed Web of Science ®Google Scholar
• Brakman P., King A. E. The fibrinolytic system in blood after retention of a dead fetus and during normal labor. Amer J Obstet Gynec 1965; 92: 221
   Google Scholar
• Brakman P., Mohler E., Astrup T. A group of patients with impaired plasma fibrinolytic system and selective inhibition of tissue activator-induced fibrinolysis. Scand J Haemat 1966; 3: 389
   PubMedGoogle Scholar
• Brakman P., Sobrero A. J., Astrup T. Effects of different systemic contraceptives on blood fibrinolysis. Amer J Obstet Gynec 1970; 106: 187
   Google Scholar
• Butler C., Hill H. Chlormadinone acetate as oral contraceptive. Lancet 1969; 1: 1116
   PubMed Web of Science ®Google Scholar
• Böttiger L. E., Westerholm B. Oral contraceptives and thromboembolic disease. Swedish experience. Acta Med Scand 1971; 190: 455
   PubMedGoogle Scholar
• Carrel A. A method for the physiological study of tissues in vitro. J Exp Med 1923; 38: 407
   Google Scholar
• Cash J. D., Allan A. G. E. The fibrinolytic response to moderate exercise and intravenous adrenaline in the same subjects. Brit J Haemat 1967; 13: 376
   PubMed Web of Science ®Google Scholar
• Celander D. R., Guest M. M. The biochemistry and physiology of urokinase. Amer J Cardiol 1960a; 6: 409
   PubMedGoogle Scholar
• Celander D. R., Guest M. M. Profibrinolysin-free fibrinogen. Fed Proc 1960b; 19: 60
   Google Scholar
• Clarke R. L., Orandi A., Cliffton E. E. Induction of fibrinolysis by venous obstruction. Angiology 1960; 11: 367
   PubMedGoogle Scholar
• Correll J. T., Sjoerdsma A. Inhibition of a human fibrinolytic system by normal and pathologic sera. Proc Soc Exp Biol (NY) 1962; 111: 274
   PubMed Web of Science ®Google Scholar
• Cronberg S. Investigations in haemorrhagic disorders with prolonged bleeding time but normal number of platelets with special reference to platelet adhesiveness. Acta Med Scand 1968, Suppl 486
   Google Scholar
• Csapo A. I., Knobil E., van der Molen H. J., Wiest W. G. Peripheral plasma progesterone levels during human pregnancy and labor. Amer J Obstet Gynec 1971; 110: 630
   PubMed Web of Science ®Google Scholar
• Daniel D. G., Campbell H., Turnbull A. C. Puerperal thromboembolism and suppression of lactation. Lancet 1967; 2: 287
   PubMed Web of Science ®Google Scholar
• Dastre A. Fibrinolyse dans le sang. Arch Physiol 1893; 5: 661
   Google Scholar
• Davies M. C., Englert M. E., De Renzo E. C. Interaction of streptokinase and human plasminogen. J Biol Chem 1964; 239: 2651
   PubMedGoogle Scholar
• Demuth F., von Riesen I. Eiweiss-stoffwechsel normaler und bösartiger Gewede in vitro. Biochem Z 1928; 203: 22
   Google Scholar
• Denk H., Schnack H., Deutsch E. Histochemischer Nachweis fibrinolytischer Aktivität in Leberbiopsien. Acta Hepato-Splenologica 1970; 17: 221
   Google Scholar
• Dixon W. J., Massey F. J. Introduction to statistical analysis. McGraw-Hill Inc., New York 1957; 290
   Google Scholar
• Downie G. R., Cliffton E. E. Variations in proteolytic activity in serum of animals including man. Proc Soc Exp Biol Med 1950; 73: 559
   Google Scholar
• Drill V. A. Oral contraceptives and thromboembolic disease. I. Prospective and retrospecive studies. J Amer Med Ass 1972; 219: 583
   Google Scholar
• Drill V. A., Calhoun D. W. Oral contraceptives and thromboembolic disease. J Amer Med Ass 1968; 206: 77
   PubMed Web of Science ®Google Scholar
• Drill V. A., Calhoun D. W. Oral contraceptives and thromboembolic disease. II. Estrogen content of oral contraceptives. J Amer Med Ass 1972; 219: 593
   Google Scholar
• Duncan I. D., Coyle M. G., Walker J. Management and treatment of 34 cases of antepartum thromboembolism. J Obstet Gynec Brit Cwlth 1971; 78: 904
   Google Scholar
• Ekelund H., Hedner U., Nilsson I. M. Fibrinolysis in newborns. Acta Paediat Scand 1970; 59: 33
   PubMed Web of Science ®Google Scholar
• El-Tomi A. E. F., Crystle C. D., Stevens V. C. Plasma human placental lactogen in late pregnancy and labor. Amer J Obstet Gynec 1970; 108: 345
   Google Scholar
• Eriksson S. Studies in α1-antitrypsin deficiency. Acta Med Scand 1965, Suppl 432
   Google Scholar
• Fearnley G. R. Fibrinolysis. Williams and Wilkins, Baltimore 1965; 45
   Google Scholar
• Fearnley G. R., Lackner R. The fibrinolytic activity of normal blood. Brit J Haemat 1955; 1: 189
   PubMedGoogle Scholar
• Finlayson J. S. “Fibrinogen”, K. Laki. Marcel Dekker, Inc., New York 1968; 53
   Google Scholar
• Fischer A. Gewebezüchtung. Verlag Rudolph Müller & Steinicke, München 1930
   Google Scholar
• Fischer A. Mechanism of the proteolytic activity of malignant tissue cells. Nature 1946; 157: 442
   PubMed Web of Science ®Google Scholar
• Fischer A. The application of soybean inhibitor in tissue cultivation. Science 1949; 109: 611
   Google Scholar
• Flanc C., Kakkar V. V., Clarke M. B. Postoperative deep-vein thrombosis effect of intensive prophylaxis. Lancet 1969; 1: 477
   Google Scholar
• Fleisher M. S., Loeb L. On tissue fibrinolysins. J Biol Chem 1915; 21: 477
   Google Scholar
• Fletcher A., Alkjaersig N., Sherry S. The maintenance of a sustained thrombolytic state in man. I. Induction and effects. J Clin Invest 1959; 38: 1096
   PubMedGoogle Scholar
• Fletcher A. P., Alkjaersig N., Sherry S. Pathogenesis of the haemorrhagic diathesis developing during “fibrinolytic” states: The significance of defective fibrin polymerization. J Clin Invest 1959; 39: 1005
   Google Scholar
• Fletcher A. P., Alkjaersig N., Sherry S., Genton E., Hirsh J., Bachmann F. The development of urokinase as a thrombolytic agent. Maintenance of a sustained thrombolytic state in man by its intravenous infusion. J Lab Clin Med 1965; 65: 713
   Google Scholar
• Ganrot P. O. Determination of α2-macroglobulin as trypsinprotein esterase. Clin Chim Acta 1966; 14: 493
   PubMed Web of Science ®Google Scholar
• Ganrot P. O., Niléhn J.-E. Competition between plasmin and thrombin for alpha2-macroglobulin. Clin Chim Acta 1967; 17: 511
   PubMed Web of Science ®Google Scholar
• Ganrot P. O., Niléhn J.-E. Immunochemical determination of human plasminogen. Clin Chim Acta 1968; 22: 335
   PubMed Web of Science ®Google Scholar
• Geiger W. B. Involvement of a complementlike factor in the activation of blood protease. J Immunol 1952; 69: 597
   Google Scholar
• Gillman T., Naidoo S. S., Hathorn M. Plasma fibrinogen activity in pregnancy. Lancet 1959; 2: 70
   Google Scholar
• Goldhaber P., Cornman I., Ormsbee R. A. Experimental alteration of the ability of tumor cells to lyse plasma clots in vitro. Proc Soc Exp Biol Med 1947; 66: 590
   Google Scholar
• Gow S., MacGillivray I. Metabolic, hormonal, and vascular changes after synthetic oestrogen therapy in oophorectomized women. Brit Med J 1971; 2: 73
   PubMed Web of Science ®Google Scholar
• Grant E. C. G. Venous effects of oral contraceptives. Brit Med J 1969; 4: 73
   PubMed Web of Science ®Google Scholar
• Groskopf W. R., Hsieh B., Summaria L., Robbins K. C. Studies on the active center of human plasmin. The serine and histidine residue. J Biol Chem 1969; 244: 359
   Google Scholar
• Hagan J. J., Ablondi F. B., de Renzo E. C. Purification and biochemical properties of human plasminogen. J Biol Chem 1960; 235: 1005
   PubMed Web of Science ®Google Scholar
• Hedner U. Purification of an activator inhibitor in serum. The International Society on Thrombosis and Haemostasis, II Congress. Villcotrykkeri Oslo 1971; 120, Abstract volume
   Google Scholar
• Hedner U., Nilsson I. M. Determination of plasminogen in human plasma by a casein method. Thrombos Diathes Haemorrh 1965; 14: 545
   PubMedGoogle Scholar
• Hedner U., Nilsson I. M. Comparison between a direct and an indirect method for determining plasminogen. Thrombosis Diathes Haemorrh 1971; 26: 289
   Google Scholar
• Hedner U., Nilsson I. M., Jacobsen C. D. Demonstration of low content of fibrinolytic inhibitors in individuals with high fibrinolytic capacity. Scand J Clin Lab Invest 1970; 25: 329
   PubMed Web of Science ®Google Scholar
• Hedner U., Åstedt B. Fibrinolytic split products in serum and urine in pregnancy. Acta Obstet Gynec Scand 1970; 49: 363
   Web of Science ®Google Scholar
• Hedner U., Åstedt B. Studies on fibrinolytic inhibitors during pregnancy. Acta Obstet Gynec Scand 1971; 50: 99
   PubMed Web of Science ®Google Scholar
• Heimburger N. Basic mechanism of action of streptokinase and urokinase. Thrombos Diathes Haemorrh Suppl 1971; 47: 21
   Google Scholar
• Heimburger N., Schwick H. G. Die Fibrinagar Elektrophorese. 2. Mitteilung: Untersuchungen zum Wirkungsmechanismus der Streptokinase. Thrombos Diathes Haemorrh 1962; 7: 444
   PubMedGoogle Scholar
• Hellem A. J. The adhesiveness of human blood platelets in vitro. Scand J Clin Lab Invest 1960, Suppl 51
   PubMed Web of Science ®Google Scholar
• Hummel B. W. C., Buck F. F., De Renzo E. C. Interaction of streptokinase and human plasminogen. J Biol Chem 1966; 241: 3474
   PubMedGoogle Scholar
• Iatridis S. G., Ferguson J. H. Effect of physical exercise on blood clotting and fibrinolysis. J Appl Physiol 1963; 18: 337
   PubMed Web of Science ®Google Scholar
• Ingemanson B. A method of reducing the fibrinolytic activity of endometrium cells in plasma clot tissue culture. Experientia 1959; 15: 159
   PubMedGoogle Scholar
• Ingemanson-Nordqvist B., Källén B. On the use of fibrinolysin inhibitors in plasma clot tissue culture. Exp Cell Res 1961; 21: 232
   Google Scholar
• Inman W. H. W., Vessey M. P. Investigation of deaths from pulmonary, coronary and cerebral thrombosis and embolism in women of childbearing age. Brit Med J 1968; 2: 193
   PubMed Web of Science ®Google Scholar
• Inman W. H. W., Vessey M. P., Westerholm B., Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the committee on safety of drugs. Brit Med J 1970; 2: 203
   PubMed Web of Science ®Google Scholar
• Isacson S. Effect of prednisolone on the coagulation and fibrinolytic systems. Scand J Haemat 1970; 7: 212
   Google Scholar
• Isacson S. Low fibrinolytic activity of blood and vein walls in venous thrombosis. Scand J Haemat 1971, Suppl 16
   Google Scholar
• Isacson S., Nilsson I. M. Defective fibrinolysis in blood and vein walls in recurrent “idiopathic” venous thrombosis. Acta Chir Scand 1972, (In press)
   Google Scholar
• Jeffcoate T. N. A., Miller J., Roos R. F., Tindall V. R. Puerperal thromboembolism in relation to the inhibition of lactation by oestrogen therapy. Brit Med J 1968; 4: 19
   PubMed Web of Science ®Google Scholar
• Johansson B. G., Malmquist J. Quantitative immunochemical determination of lysozyme in serum and urine. Scand J Clin Lab Invest 1971; 27: 255
   PubMed Web of Science ®Google Scholar
• Johnson A. J., Skoza L., Tse A. O. Studies on plasmin inhibition and plasminogen activation and its inhibition. Thrombos Diathes Haemorrh Suppl 1969; 32: 105
   Google Scholar
• Kaplan M. J. Nature and role of lytic factor in hemolytic streptococcal fibrinolysis. Proc Soc Exp Biol Med 1944; 57: 40
   Google Scholar
• Kawano T., Morimoto K., Uemura Y. Urokinase inhibitor in human placenta. Nature 1968; 217: 253
   PubMed Web of Science ®Google Scholar
• Kline D. L., Ts'ao C.-H. Activation of human plasminogen by streptokinase in the absence of Sk-plasmin complex. Amer J Physiol 1971; 220: 440
   Google Scholar
• Kok P., Astrup T. Isolation and purification of a tissue plasminogen activator and its comparison with urokinase. Biochemistry 1969; 8: 79
   PubMed Web of Science ®Google Scholar
• Konttinen Y. P. Fibrinolysis. Oy Star AB, Tampere, Finland 1968; 76
   Google Scholar
• Kowalski E., Budzynski A., Kopec M., Murawski K. Dysproteinemia induced in vitro by plasmin digestion of fibrinogen. Blood 1960; 15: 164
   Google Scholar
• Kucinski C. S., Fletcher A. P., Sherry S. Effect of urokinase antiserum on plasminogen activators: Demonstration of immunologic dissimilarity between plasma plasminogen activator and urokinase. J Clin Invest 1968; 47: 1238
   Google Scholar
• Kullander S., Källén B. The fibrinolytic activity of human endometrium, studies in tissue culture. II. Carcinoma of the uterine body. Acta Obstet Gynec Scand 1961; 40: 234
   Web of Science ®Google Scholar
• Kunitz M., Northrop J. H. Isolation from beef pancreas of crystalline trypsinogen, trypsin, a trypsin inhibitor and an inhibitor-trypsin compound. J Gen Physiol 1936; 19: 991
   PubMedGoogle Scholar
• Kwaan H. C., Astrup T. Demonstration of cellular fibrinolytic activity by the histochemical fibrin slide technique. Lab Invest 1967; 17: 140
   PubMed Web of Science ®Google Scholar
• Kwaan H. C., Fischer S. Localization of fibrinolytic activity in kidney tissues. Fed Proc 1965; 24: 387
   Google Scholar
• Källén B., Röhl L. The fibrinolytic activity of human hyperplastic prostatae studied in tissue culture. Acta Chir Scand 1959/1960; 118: 240
   Google Scholar
• Lack C. H., Ali Y. S. Tissue activator of plasminogen. Nature 1964; 201: 1030
   Google Scholar
• Ladehoff A. A. The content of plasminogen activator in the human urinary tract. Scand J Clin Lab Invest 1960; 12: 136
   Google Scholar
• Lambert R. A., Hanes Fr. M. Characteristics of growth of sarcoma and carcinoma cultuvated in vitro. J Exp Med 1911; 13: 495
   Google Scholar
• Larrieu M. J. Action of fibrinogen degradation products and fibrin monomer soluble complexes on platelet aggregation. Scand J Haemat Suppl 1971; 13: 273
   PubMedGoogle Scholar
• Lassen M. Heat denaturation of plasminogen in the fibrin plate method. Acta Physiol Scand 1952; 27: 371
   Google Scholar
• Laurell C. B. Quantitatative estimation of proteins by electrophoresis in agarose gel containing antibodies. Analyt Biochem 1966; 15: 45
   PubMed Web of Science ®Google Scholar
• Lauritsen O. S. Urokinase inhibitor in human plasma. Scand J Clin Lab Invest 1968; 22: 314
   PubMed Web of Science ®Google Scholar
• Lauritsen O. S. The fibrinolytic enzyme system of human blood plasma in pregnancy. Scand J Clin Lab Invest 1969; 23: 191
   PubMed Web of Science ®Google Scholar
• Lesuk A., Terminiello L., Traver J. H. Crystalline human urokinase: some properties. Science 1965; 147: 880
   Google Scholar
• Lewis J. H., Ferguson J. H. Studies on a proteolytic enzyme system of the blood. I. Fibrinolysokinase activators for profibrinolysin. J Clin Invest 1950; 29: 1059
   PubMed Web of Science ®Google Scholar
• Lipinski B., Wegrzynowicz Z., Budzynski A. Z., Kopec M., Latallo Z. S., Kowalski E. Soluble unclottable complexes formed in the presence of fibrinogen degradation products (FDP) during the fibrinogen-fibrin conversion and their potential significance in pathology. Thrombos Diathes Haemorrh 1967; 17: 65
   PubMedGoogle Scholar
• Loeb L. Über die Entstehung von Bindegewebe, Leucocyten und roten Blutkörperchen aus Epithel und über eine Methode, isolierte Gewebeteile zu züchten. M. Stern and Co., Chicago 1897
   Google Scholar
• McConnel D., Johnson J. G., Joung I., Holemans R. Localization of plasminogen activator activity in kidney tissue. Lab Ínvest 1966; 15: 980
   PubMed Web of Science ®Google Scholar
• Macfarlane R. G. Fibrinolysis following operation. Lancet 1937; 1: 10
   Google Scholar
• Macfarlane R. G., Biggs R. Observations on fibrinolysis. Spontaneous activity associated with surgical operations, trauma, etc. Lancet 1946; 2: 862
   PubMedGoogle Scholar
• Macfarlane R. G., Biggs R. Fibrinolysis, Its mechanism and significance. Blood 1948; 3: 1167
   PubMed Web of Science ®Google Scholar
• McQueen E. G. Oestrogen content of oral contraceptives and thromboembolism. New Zeal Med J 1970; 71: 317
   Google Scholar
• Marder V. J. Identification and purification of fibrinogen degradation products produced by plasmin: considerations on the structure of fibrinogen. Scand J Haemat 1971a; 21, Suppl 13
   Google Scholar
• Marder V. J. Fibrinogen and fibrin degradation products. Physicochemical and physiological considerations. Thrombos Diathes Haemorrh Suppl 1971b; 47: 85
   Google Scholar
• Markwardt F., Klöcking H. P., Landmann H. Vergleichende Untersuchungen über Antifibrinolytika. Thrombos Diathes Haemorrh 1967; 15: 561
   Google Scholar
• Markwardt F., Perlewitz J. Die Hemmung der fibrinolytischen Wirkung von Gewebekulturen durch Antifibrinolytika. Naturwissenschaften 1963; 50: 502
   Google Scholar
• Menon S., Peberdy M., Rannie G. H., Weightman D., Dewar H. A. A comparative study of blood fibrinolytic activity in normal women, pregnant women and women on oral contraceptives. J Obstet Gynaec Brit Cwlth 1970; 77: 752
   Google Scholar
• Mole R. H. Fibrinolysin and the fluidity of the blood post mortem. J Path Bact 1948; 60: 413
   Google Scholar
• Morgan J. F., Parker G. Use of antitrypsin agents in tissue culture. I. Crude soybean-inhibitor. Proc Soc Exp Biol Med 1949; 71: 665
   Google Scholar
• Mosesson M. W. The preparation of human fibrinogen free of plasminogen. Biochim Biophys Acta 1962; 57: 204
   PubMedGoogle Scholar
• Moxley R. T., Brakman P., Astrup T. Resting levels of fibrinolysis in blood in inactive and exercising men. J Appl Physiol 1970; 28: 549
   PubMed Web of Science ®Google Scholar
• Müllertz S. Effect of carboxylic and amino acids on fibrinolysis produced by plasmin, plasminogen activator and proteases. Proc Soc Exp Biol Med 1954; 85: 326
   Google Scholar
• Müllertz S. Formation and properties of the activator of plasminogen and of human and bovine plasminogen. Biochem J 1955; 61: 424
   PubMed Web of Science ®Google Scholar
• Müllertz S. Mechanism of activation and effect of plasmin in blood. Acta Physiol Scand 1956; 38, Suppl 130
   Google Scholar
• Müllertz S. Activation of plasminogen. Ann N Y Acad Sci 1957; 68: 38
   Google Scholar
• Müllertz S., Lassen M. An activator system in blood indispensable for formation of plasmin by streptokinase. Proc Soc Exp Biol Med 1953; 82: 264
   PubMed Web of Science ®Google Scholar
• Nakahara M., Celander D. R. Properties of microsomal activator of profibrinolysin found in bovine and porcine heart muscle. Thrombos Diathes Haemorrh 1968; 19: 482
   Google Scholar
• Niléhn J.-E. Split products of fibrinogen after prolonged interaction with plasmin. Thrombos Diathes Haemorrh 1967a; 18: 89
   PubMedGoogle Scholar
• Niléhn J.-E. Separation and estimation of “split products” of fibrinogen and fibrin in human serum. Thrombos Diathes Haemorrh 1967b; 18: 487
   PubMedGoogle Scholar
• Niléhn J.-E. Influence of split products of fibrinogen on results of blood coagulation tests and platelet adhesiveness. Scand J Haemat 1967c; 4: 430
   Google Scholar
• Niléhn J.-E., Ganrot P. O. Plasmin, plasmin inhibitors and degradation products of fibrinogen in human serum during and after intravenous infusion of streptokinase. Scand J Clin Lab Invest 1967; 20: 113
   Web of Science ®Google Scholar
• Nilsson I. M. Changes in the coagulation and fibrinolytic systems predisposing to thrombosis. Acta Chir Scand Suppl 1967; 387: 15
   Google Scholar
• Nilsson I. M., Andersson L., Björkman S. E. Epsilon-aminocaproic acid (EACA) as a therapeutic agent. Based on 5 year's clinical experience. Acta Med Scand 1966, Suppl 448
   Google Scholar
• Nilsson I. M., Blombäck B., von Francken I. On an inherited autosomal haemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med Scand 1957; 159: 35
   PubMedGoogle Scholar
• Nilsson I. M., Krook H., Sternby N. H., Söderberg E., Söderström N. Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor of the fibrinolytic system. Acta Med Scand 1961; 169: 323
   PubMed Web of Science ®Google Scholar
• Nilsson I. M., Kullander S. Coagulation and fibrinolytic studies during pregnancy. Acta Obstet Gynec Scand 1967; 46: 273
   PubMed Web of Science ®Google Scholar
• Nilsson I. M., Kullander S., Åstedt B. Coagulation and fibrinolytic studies during continuous of low dose gestagen. Acta Endocrin 1970; 65: 111
   Google Scholar
• Nilsson I. M., Olow B. Determination of fibrinogen and fibrinogenolytic activity. Thrombos Diathes Haemorrh 1962; 8: 297
   PubMedGoogle Scholar
• Nilsson I. M., Pandolfi M. Fibrinolytic response of the vascular wall. Thrombos Diathes Haemorrh Suppl 1970; 40: 231
   Google Scholar
• Nilsson I. M., Pandolfi M., Robertson B. Properties of fibrinolytic activators appearing after venous stasis and intravenous injection of nicotinic acid. Coagulation 1970; 3: 13
   Google Scholar
• Nilsson I. M., Sjoerdsma A., Waldenström J. Antifibrinolytic activity and metabolism of E-aminocaproic acid in man. Lancet 1960; 1: 1322
   PubMedGoogle Scholar
• Norman P. S., Hill B. M. Studies on the plasmin system. III. Physical properties of the two plasmin inhibitors in plasma. J Exp Med 1958; 108: 639
   PubMed Web of Science ®Google Scholar
• Nussenzweig V., Seligmann M. Analyse par des méthodes immunochimiques, de la dégradation par la plasmine du fibrinogéne humain et de la fibrine, à différents stades. Rev Hémat 1960; 15: 451
   Google Scholar
• Nussenzweig V., Seligmann M., Pelmont J., Grabar P. Les produits de dégradation du fibrinogène humaine par la plasmine. Ann Inst Pasteur 1961; 100: 377
   PubMedGoogle Scholar
• Okamoto S., Nagasawa S., Tagaki E., Tsukada Y., Koyoi M., Sato M. Ref. to British Patent Specification 1957; 770: 693
   Google Scholar
• Okamoto S., Okamoto U. Amino-metyl-cyclohexanecarboxylic acid: AMCHA. A new potent inhibitor of the fibrinolysis. Keio J Med 1962; 11: 105
   Google Scholar
• Oliver M. F. Thrombosis and oestrogens. Lancet 1967; 2: 510
   PubMed Web of Science ®Google Scholar
• Owren P. A., Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest 1951; 3: 201
   PubMed Web of Science ®Google Scholar
• Painter R. H., Charles A. F. Characterization of a soluble plasminogen activator from kidney cell cultures. Amer J Physiol 1962; 202: 1125
   PubMedGoogle Scholar
• Pandolfi M. Studies on fibrinolysis in some tissues and in aqueous humor. Thesis, Berlingska Boktryckeriet, Lund 1969
   Google Scholar
• Pandolfi M. Persistence of fibrinolytic activity in fragments of human veins cultured in vitro. Thrombos Diathes Haemorrh 1970; 24: 43
   Google Scholar
• Pandolfi M., Bergentz S.-E., Claes G., Ljungqvist U. (1971) Localization of fibrinolytic activity in healthy and diseased renal tissue. Microcirculatory Approaches to Current Therapeutic Problems. Symposia. 6th Europ Conf Microcirculation, Aalborg, 1970. Karger, Basel, 88
   Google Scholar
• Pandolfi M., Hedner U., Nilsson I. M. Bilateral occlusion of the retinal veins in a patient with inhibition of fibrinolysis. Ann Ophthal 1970; 2: 481
   Google Scholar
• Pandolfi M., Isacson S., Nilsson I. M. Low fibrinolytic activity in the walls of veins in patients with thrombosis. Acta Med Scand 1969; 186: 1
   PubMedGoogle Scholar
• Pandolfi M., Nilsson I. M., Robertson B., Isacson S. Fibrinolytic activity of human veins. Lancet 1967; 2: 127
   Google Scholar
• Pandolfi M., Robertson B., Isacson S., Nilsson I. M. Fibrinolytic activity of human veins in arms and legs. Thrombos Diathes Haemorrh 1968; 20: 247
   PubMedGoogle Scholar
• Pandolfi M., Åstedt B., Nilsson I. M. Histochemical assay of tissue plasminogen activator in vein walls a standard method. Thrombos Diathes Haemorrh 1972, (In press)
   Google Scholar
• Paraskevas M., Nilsson I. M., Martinsson G. A method for determining serum inhibitors of plasminogen activation. Scand J Clin Lab Invest 1962; 14: 138
   PubMed Web of Science ®Google Scholar
• Ploug J., Kjeldgaard N. O. Urokinase, an activator of plasminogen from human urine. I. Isolation and properties. Biochem Biophys Acta 1957; 24: 278
   PubMed Web of Science ®Google Scholar
• Powell L. C., Seymour R. J. Effects of depo-medroxyprogesterone acetate as a contraceptive agent. Amer J Obstet Gynec 1971; 110: 36
   Google Scholar
• Pugatch E. M. J., Poole J. C. F. Inhibitor of fibrinolysis from mesothelium. Nature 1969; 221: 269
   Google Scholar
• Rado A., Crystle C. D., Townsley J. D. Concentrations of estrogens in maternal peripheral plasma in late pregnancy, during labor and post partum. J Clin Endocrin 1970; 30: 497
   PubMedGoogle Scholar
• Remmert L. F., Cohen P. P. Partial purification and properties of a proteolytic enzyme of human serum. J Biol Chem 1949; 181: 431
   PubMed Web of Science ®Google Scholar
• de Renzo E. C., Boggiano E., Hummel B. C. W. Interaction of streptokinase with human plasminogen and human plasmin. Fed Proc 1965; 24: 260
   Google Scholar
• Rimon A., Shamash Y., Shapiro B. The plasmin inhibitor of human plasma. J Biol Chem 1966; 241: 5102
   PubMed Web of Science ®Google Scholar
• Robertson B. On thrombosis, thrombolysis and fibrinolysis. Acta Chir Scand 1971, Suppl 421
   Google Scholar
• Robertson B. R., Nilsson I. M., Nylander G. Thrombolytic effect of streptokinase as evaluated by phlebography of deep venous thrombi of the leg. Acta Chir Scand 1970; 136: 173
   Google Scholar
• Robbins K. C., Summaria I. Biochemistry of fibrinolysis. Thrombos Diathes Haemorrh Suppl 1971; 47: 9
   Google Scholar
• Robbins K. C., Summaria L., Elwyn D., Barlow G. H. Further studies on the purification and characterization of human plasminogen and plasmin. J Biol Chem 1965; 240: 541
   Google Scholar
• Robbins K. C., Summaria L., Hsieh B., Shah R. H. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967; 242: 2333
   PubMed Web of Science ®Google Scholar
• Roy E. J., Harkness R. A., Kerr M. G. The concentration of oestrogens in maternal peripheral blood during and after labour. J Obstet Gynaec Brit Cwlth 1963; 70: 1034
   Google Scholar
• Santesson L. Characteristics of epithelial mouse tumour cells in vitro and tumour structures in vivo. A comparative study. Acta Path Microbiol Scand 1935, Suppl 24
   Google Scholar
• Sartwell P. E., Masi A. T., Arthes F. G., Greene G. R., Smith H. E. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Amer J Epidem 1969; 90: 365
   PubMed Web of Science ®Google Scholar
• Shamash Y., Rimon A. The plasmin inhibitors of plasma. I. A method for their estimation. Thrombos Diathes Haemorrh 1964; 12: 119
   PubMedGoogle Scholar
• Shaper A. G., Kear J., Macintosh D. M., Kyobe J., Njama D. The platelet count, platelet adhesiveness and aggregation and the mechanism of fibrinolytic inhibition in pregnancy and the puerperium. J Obstet Gynaec Brit Cwlth 1968; 75: 433
   PubMedGoogle Scholar
• Shaper A. G., Macintosh D. M., Evans C. M., Kyobe J. Fibrinolysis and plasminogen levels in pregnancy and the puerperium. Lancet 1965; 2: 706
   Google Scholar
• Shaper A. G., Macintosh D. M., Kyobe J. Fibrinolytic activity in pregnancy, during parturition and in the puerperium. Lancet 1966; 2: 874
   Google Scholar
• Sherry S., Alkjaersig N., Fletcher A. P. Activity of plasmin and streptokinase-activator on substituted arginine and lysine esters. Thrombos Diathes Haemorrh 1966; 16: 18
   Google Scholar
• Sherry S., Lindemeyer R. I., Fletcher A. P., Alkjaersig N. Studies on enhanced fibrinolytic activity in man. J Clin Invest 1959; 38: 810
   PubMed Web of Science ®Google Scholar
• Siegel-Ralston A.-M., Astrup T. Previously undescribed fibrinolysis inhibitor in human blood. Nature 1971; 234: 180
   Google Scholar
• Sjoerdsma A., Nilsson I. M. Aliphatic amino compounds as inhibitors of plasminogen activation. Proc Soc Exp Biol Med 1960; 103: 533
   Google Scholar
• Sobrero A. J., Brakman P., Astrup T. Effects on blood fibrinolysis of an oral contraceptive low in progestin (Ovulen). Amer J Obstet Gynec 1971; 110: 122
   Google Scholar
• Summaria L., Hsieh B., Groskopf W. R., Robbins K. C. The isolation and characterization of the S-carboxymethyl ß (light) chain derivative of human plasmin. The localization of the active site on the ß (light) chain. J Biol Chem 1967b; 242: 5046
   Google Scholar
• Summaria L., Hsieh B., Groskopf W. R., Robbins K. C. Direct activation of human plasminogen by streptokinase. Proc Soc Exp Biol (NY) 1969; 130: 737
   Google Scholar
• Summaria L., Hsieh B., Robbins K. C. The specific mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967a; 242: 4279
   Google Scholar
• Summaria L., Robbins K. C., Barlow G. H. Isolation and characterization of the S-carboxymethyl heavy chain derivative of human plasmin. J Biol Chem 1971; 246: 2143
   Google Scholar
• Tagnon H. J., Palade G. E. Activation of proplasmin by a factor from mammalian tissue. J Clin Invest 1950; 29: 317
   PubMed Web of Science ®Google Scholar
• Tagnon H. J., Peterman M. L. Activation of proplasmin by a tissue fraction. Proc Soc Exp Biol Med 1949; 70: 359
   PubMed Web of Science ®Google Scholar
• Takada A., Takada Y., Ambrus J. L. Streptokinase-activatable proactivator of human and bovine plasminogen. J Biol Chem 1970; 245: 6389
   Google Scholar
• Takada A., Takada Y., Ambrus L. Proactivators in the fibrinolytic system. Thrombos Diathes Haemorrh Suppl 1971; 47: 37
   Google Scholar
• Takada Y., Takada A., Ambrus J. L. Comparative study of proactivators of the fibrinolysin system in three mammalian species. Thrombos Diathes Haemorrh 1969; 21: 594
   Google Scholar
• Todd A. S. Histological localization of fibrinolysin activator. J Path Bact 1959; 78: 281
   PubMedGoogle Scholar
• Triantaphyllopoulos D. C., Triantaphyllopoulos E., Chandra S. Effect of fibrin(ogen) degradation products on coagulation. Thrombos Diathes Haemorrh Suppl 1971; 47: 121
   Google Scholar
• Triantaphyllopoulos E., Triantaphyllopoulos D. C. Variability of the anticoagulant fraction of incubated fibrinogen. Amer J Physiol 1965; 208: 521
   PubMedGoogle Scholar
• Vessey M. P., Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Brit Med J 1969; 2: 651
   PubMed Web of Science ®Google Scholar
• Vignal A., Blatrix Ch., Steinbuch M. Fibrinogen free of plasminogen as substrate for fibrinolytic assays. Nature 1962; 193: 693
   Google Scholar
• Villasanta U. Thromboembolic disease in pregnancy. Amer J Obstet Gynec 1965; 93: 142
   PubMed Web of Science ®Google Scholar
• Wallén P. Plasmin degradation of fibrinogen. Scand J Haemat. Suppl 1971; 13: 3
   PubMedGoogle Scholar
• Wallén P., Bergström K. Purification of human plasminogen on DEAE-cellulose. Acta Chem Scand 1960; 14: 217
   Google Scholar
• White W. F., Barlow G. H., Mozen M. M. The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 1966; 5: 2160
   PubMed Web of Science ®Google Scholar
• Wolf P. A modification for routine laboratory use of Stefanini's method of estimating factor V activity in human oxalated plasma. J Clin Path 1953; 6: 34
   PubMed Web of Science ®Google Scholar
• Woodfield D. G., Cole S. K., Cash J. D. Impaired fibrinolytic response to exercise stress in normal pregnancy. Amer J Obstet Gynec 1968; 102: 440
   Google Scholar
• Yannone M. E., McCurdy J. R., Goldfien A. Plasma progesterone levels in normal pregnancy, labor and the puerperium. Amer J Obstet Gynec 1968; 101: 1058
   PubMed Web of Science ®Google Scholar
• Ygge J. Changes in blood coagulation and fibrinolysis during the puerperium. Amer J Obstet Gynec 1969; 104: 2
   Google Scholar
• Åstedt B., Svanberg L., Nilsson I. M. Fibrin degradation products and ovarian tumours. Brit Med J 1971; 4: 458
   PubMedGoogle Scholar